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Background: Several studies on the association of TNF-alpha (−308 G/A), IL-6 (−174 G/C) and IL-1beta (−511 C/T)
polymorphisms with polycystic ovary syndrome (PCOS) risk have reported conflicting results. The aim of the present
study was to assess these associations by meta-analysis.
Results: A total of 14 eligible articles (1665 cases/1687 controls) were included in this meta-analysis. The results
suggested that there was no obvious association between the TNF-alpha (−308 G/A) polymorphism and PCOS in
the overall population or subgroup analysis by ethnicity, Hardy–Weinberg equilibrium (HWE) in controls, genotyping
method, PCOS diagnosis criteria, and study sample size. Also, no obvious association was found between the
TNF-alpha (−308 G/A) polymorphism and obesity in patients with PCOS (body mass index [BMI] ≥ 25 kg/m2 vs.
BMI < 25 kg/m2). Regarding the IL-6 (−174 G/C) polymorphism, also no association was found in the overall
population in heterozygote comparison, dominant model, and recessive model. Even though an allelic model
(odds ratio [OR] = 0.63, 95% confidence interval [CI] = 0.41–0.96) and a homozygote comparison (OR = 0.52,
95% CI = 0.30–0.93) showed that the IL-6 (−174 G/C) polymorphism was marginally associated with PCOS.
Further subgroup analysis suggested that the effect size was not significant among HWE in controls (sample
size ≤ 200) and genotyping method of pyrosequencing under all genetic models. Similarly, there was no association
between the IL-1beta (−511 C/T) polymorphism and PCOS in the overall population or subgroup analysis under all
genetic models. Furthermore, no significant association was found between the IL-1beta (−511 C/T) polymorphism
and several clinical and biochemical parameters in patients with PCOS.
Conclusions: The results of this meta-analysis suggest that the TNF-alpha (−308 G/A), IL-6 (−174 G/C), and IL-1beta
(−511 C/T) polymorphisms may not be associated with PCOS risk. However, further case–control studies with
larger sample sizes are needed to confirm our results.
Keywords: Polycystic ovary syndrome, TNF-alpha, IL-6, IL-1beta, Polymorphism, Meta-analysisBackground
Polycystic ovary syndrome (PCOS) is a common and
complex endocrine disorder leading to reproductive dys-
function in females, with a prevalence of 5%–10% [1].
Hyperandrogenism, oligo/anovulation, polycystic ovaries,
hyperinsulinemia, and obesity are main manifestations of
PCOS with a subsequent increased risk for type 2 diabetes
[2]. Although the etiology of PCOS remains controversial,* Correspondence: lh_znn@126.com
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reportedly associated with PCOS [3].
Recent studies have shown that chronic low grade in-
flammation is closely related to the incidence of PCOS
[4]. Pro-inflammatory cytokines, such as tumor necrosis
factor alpha (TNF-alpha), interleukin (IL)-6, and IL-1,
are prominent mediators of inflammation and have been
confirmed to be elevated in at least a subgroup of
women with PCOS [5-7]. The corpus luteum secretes
TNF-alpha and the levels of immunoreactive TNF-alpha
vary throughout the menstrual cycle [8]. TNF-alpha, IL-6,
and IL-1 are presumed to play pivotal roles in repro-
ductive physiology, including regulation of ovarian steroidis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ovulation, fertilization, and implantation– parameters all
affected in women with PCOS [9,10].
The TNF-alpha gene resides within the class III region
of the major histocompatibility complex and is located on
the short arm of chromosome 6 (6p21.3). A single nucleo-
tide polymorphism (SNP) located at position −308 in the
promoter region of the TNF-alpha gene gives rise to a
G-A exchange, which has been associated with elevated
serum TNF-alpha concentrations in certain clinical states
[5,11]. The human IL-6 gene is located at chromosome
7p21-24 and has an upstream 303 bp promoter. A SNP,
which results in exchange of G-C at position −174 in the
promoter region of the IL-6 gene, has been found to
influence its transcription rate [12]. The IL-1 gene cluster
on chromosome 2q12-13 contains three related genes,
IL-1alpha, IL-1beta, and IL-1RN. A common C/T SNP of
the IL-1beta promoter at position −511 has been found to
correspond with altered IL-1beta protein expression both
in vitro and in vivo [13].
Recently, a number of research groups have evalu-
ated the usefulness of the TNF-alpha (−308 G/A), IL-6
(−174 G/C), and IL-1beta (−511 C/T) polymorphisms as
potential susceptibility factors for PCOS. However, the re-
sults of published studies are inconclusive and even con-
troversial [7,14-26], which could be due to differences in
the studied populations and limited sample sizes. There-
fore, in this study, a meta-analysis of 14 eligible articles
was performed to clarify these inconsistences and provide
more conclusive results.
Methods
Publication search and inclusion criteria
To identify all published reports on the association between
TNF-alpha (−308 G/A), IL-6 (−174 G/C), and IL-1beta
(−511 C/T) polymorphisms and PCOS risk, we performed
a systematic literature search of PubMed, ISI Web of
Science, Elsevier Science Direct, China Biology Medical
Literature Database, China National Knowledge Infrastructure,
and Wanfang online libraries using the terms “polymorph-
ism or variant or mutation” and “polycystic ovary syndrome
or PCOS” and “tumor necrosis factor alpha or TNF-alpha
or interleukin-6 or IL-6 or interleukin-1beta or IL-1beta”
without any language restrictions. We also conducted a
manual search of references in the individual articles to
identify other potential publications. All clearly irrelevant
studies, case reports, editorials, and review articles were
excluded. The literature search was updated on September
15, 2014. This meta-analysis was conducted and reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-Analysis (PRISMA) Statement [27] (see
the checklist included in Additional file 1).
Eligible studies were selected according to the following
explicit inclusion criteria: (1) evaluated the associationbetween TNF-alpha (−308 G/A), IL-6 (−174 G/C) and
IL-1beta (−511 C/T) polymorphisms and susceptibility
to PCOS; (2) case–control studies based on unrelated in-
dividuals; (3) all patients met the diagnostic criteria for
PCOS; (4) must provide sufficient genotype data to calcu-
late odds ratios (ORs) and 95% confidence intervals (CIs).
Articles that did not meet our inclusion criteria were ex-
cluded. When a study reported the results on different
ethnicities, we treated them independently.
Data extraction
Two authors independently extracted all data based on
the inclusion criteria listed above. Any disagreement was
subsequently resolved by consensus with a third author.
The following items were collected from each study: the
first author’s name, year of publication, source of publi-
cation, ethnicity of the population, sample size, PCOS
diagnostic criteria, genotyping method, genotype frequen-
cies, and probability (p) value for the Hardy–Weinberg
equilibrium (HWE) in controls. If original genotype fre-
quency data were unavailable in relevant articles, a request
for additional data was sent to the corresponding author.
Quality assessment
Two reviewers independently assessed the quality of every
included study according to the Newcastle-Ottawa Scale
(NOS) (www.ohri.ca/programs/clinical_epidemiology/oxford.
asp). This scale contains nine items (1 point for each) in
three parts relating to selection, comparability and ascer-
tainment of exposure. A score of five or more was defined
as having high quality; otherwise, the study was regarded
as "low quality" [28].
Statistical analysis
Crude ORs with 95% CIs were used to assess the associ-
ation between TNF-alpha (−308 G/A), IL-6 (−174 G/C)
and IL-1beta (−511 C/T) polymorphisms with PCOS
risk. Analysis of polymorphisms was conducted in at
least two studies. The pooled OR was calculated for the
allele model, homozygote comparison, heterozygote
comparison, dominant model, and recessive model. The
Z test was used to estimate the statistical significance of
pooled ORs and a p-value < 0.05 was considered statisti-
cally significant. Genotype frequencies of healthy controls
were tested for HWE using the χ2 test. The Cochran Q
test and I2 test were used to evaluate potential heterogen-
eity between studies. Significant heterogeneity was indi-
cated by p < 0.10 for the Q test or I2 test of > 50% [29].
The pooled ORs were analyzed using the random effects
model [30]. Otherwise, the fixed effects model [31] was se-
lected. Subgroup analyses were conducted to explore rea-
sons for heterogeneity. In order to evaluate the influence
of single studies on the overall estimate, sensitivity analysis
was performed. Potential publication bias was diagnosed
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ence of publication bias was indicated by a p-value < 0.05
[32,33]. Data management and analysis were performed
using STATA statistical software (version 12.0; Stata
Corporation, College Station, TX, USA).
Results
Characteristics of included studies
The literature search identified a total of 326 potentially
relevant papers. There were 272 potentially relevant pa-
pers after duplicates were removed. After review of the
titles and abstracts of all articles, 242 were excluded; full
texts were also reviewed and 16 articles were further ex-
cluded. Finally, a total of 14 eligible articles with a total
of 1665 PCOS patients and 1687 healthy subjects met
the inclusion criteria and were included in this meta-
analysis [7,14-26], with one study that included both
TNF-alpha (−308 G/A) and IL-6 (−174 G/C) polymor-
phisms [22]. The flow chart in Figure 1 is a summary of











































Figure 1 Flow diagram of the study selection process.summarized in Table 1. Overall, six studies were con-
ducted among Caucasians and eight among Asians. The
Rotterdam diagnostic criteria were used in 12 studies
and the NIH criteria in two. In 8 of 14 studies, DNA
was extracted from peripheral blood and analyzed with a
classic polymerase chain reaction–restriction fragment
length polymorphism (PCR–RFLP) assay. The NOS re-
sults showed that the median overall score was 6 (range,
4–8). Thirteen studies were considered high quality and
one as low quality. In addition, four studies reported a
deviation of the genotype distributions among the con-
trols from the HWE [17,21,23,25].
Meta-analysis results
A total of 802 cases and 802 controls were assessed to
identify associations between the TNF-alpha (−308 G/A)
polymorphism and PCOS. The A allele was considered
as the risk variant. However, we found no association be-
tween the TNF-alpha (−308 G/A) polymorphism and
PCOS risk in the overall population (A vs. G: OR = 0.93,moved
242 were excluded:
Irrelevant to research topics (n = 221);
Not human studies (n = 5);
Case reports, letters, reviews, meta-
analysis (n = 16).
sed 
16 were excluded:
Studies without sufficient data (n = 3);
Overlapped studies (n = 1);
Irrelevant to TNF-alpha (−308 G/A), IL-6 
(−174 G/C) and IL-1beta (−511 C/T)
polymorphisms (n = 12).
 
s
ditional articles identified 
ough a manual searching
(n =  1)
IL-1beta (−511 C/T)
(n = 4)
Table 1 Characteristic of the studies included in this meta-analysis








Cases Controls Cases Controls 11 12 22
TNF-alpha (−308 G/A)
Milner et al. [14] 1999 Australia Caucasian NA NA 84 108 NIH criteria PCR-SSCP 4 59/63 23/42 2/3 0.194
Mao et al. [15] 2000 China Asian 28.0 ± 0.5 31.1 ± 1.1 118 54 NIH criteria PCR-RFLP 6 88/37 29/13 1/4 0.089
Vural et al. [22] 2010 Turkey Caucasian 25 (17–39)a 27 (18–39)a 97 95 Rotterdam criteria PCR-RFLP 8 78/77 16/15 3/3 0.055
Zhang et al. [16] 2010 China Asian 29.0 ± 1.5 30.0 ± 1.5 78 40 Rotterdam criteria Microarray 7 72/36 6/4 0/0 0.739
Deepika et al. [17] 2013 India Asian NA NA 283 306 Rotterdam criteria ARMS PCR 6 10/10 270/293 3/3 <0.05
Wen et al. [18] 2013 China Asian 26.86 ± 4.5 27.3 ± 3.71 103 59 Rotterdam criteria PCR-RFLP 8 89/52 14/7 0/0 0.628
Grech et al. [19] 2014 Greece Caucasian 22.5 ± 3.2 NA 39 140 Rotterdam criteria PCR-RFLP 5 33/125 6/14 0/1 0.394
IL-6 (−174 G/C)
Walch et al. [20] 2004 Austria Caucasian 28 (20–39)a NA 62 94 Rotterdam criteria Pyrosequencing 6 24/43 30/35 8/16 0.068
Erdogan et al. [21] 2009 Turkey Caucasian 24.07 ± 1.32 25.01 ± 2.05 88 119 Rotterdam criteria PCR-RFLP 8 57/32 26/75 5/12 <0.05
Vural et al. [22] 2010 Turkey Caucasian 25 (17–39)a 27 (18–39)a 97 95 Rotterdam criteria PCR-RFLP 8 59/46 34/42 4/7 0.536
Tumu et al. [23] 2013 India Asian 26.35 ± 3.88 30.00 ± 5.17 104 156 Rotterdam criteria Pyrosequencing 6 69/77 31/73 4/6 <0.05
IL-1beta (−511 C/T)
Kolbus et al. [24] 2007 Austria Caucasian 27.9 ± 5.0 28.8 ± 5.9 105 102 Rotterdam criteria Pyrosequencing 7 43/40 47/48 15/14 0.947
Yang et al. [25] 2009 China Asian NA NA 118 86 Rotterdam criteria PCR-RFLP 5 30/34 56/26 32/26 <0.05
Mu et al. [26] 2010 China Asian 26.91 ± 4.02 31.14 ± 4.22 200 177 Rotterdam criteria PCR-RFLP 6 64/26 76/87 60/64 0.684
Xia et al. [7] 2013 China Asian 29.75 ± 3.62 28.93 ± 3.91 59 56 Rotterdam criteria PCR-RFLP 6 13/18 21/31 25/7 0.257
For TNF-alpha (−308 G/A), 11 = GG, 12 = GA, 22 = AA; For IL-6 (−174 G/C), 11 = GG, 12 = GC, 22 = CC; For IL-1beta (−511 C/T), 11 = CC, 12 = CT, 22 = TT.
NA, not available; HWE, Hardy–Weinberg equilibrium; PCR-RFLP, polymerase chain reaction–restriction fragment length polymorphism; SSCP, single-strand conformational polymorphism; ARMS, amplification refractory













Table 2 Meta-analysis of TNF-alpha (−308 G/A) polymorphism and PCOS risk
Comparison No. of
studies
A vs. G AA vs. GGa GA vs. GG AA + GA vs. GG AA vs. GA + GGa
OR (95% CI) PH OR (95% CI) PH OR (95% CI) PH OR (95% CI) PH OR (95% CI) PH
Overall 7 0.93 (0.77-1.11)F 0.610 0.61 (0.26-1.41)F 0.519 0.89 (0.65-1.23)F 0.725 0.85 (0.63-1.16)F 0.741 0.66 (0.29-1.49)F 0.495
HWE in controls/
sample size ≤ 200
6 0.82 (0.61-1.10)F 0.634 0.53 (0.20-1.39)F 0.397 0.89 (0.63-1.25)F 0.603 0.84 (0.61-1.17)F 0.625 0.55 (0.21-1.44)F 0.389
PCR-RFLP 4 0.91 (0.63-1.32)F 0.469 0.47 (0.15-1.47)F 0.236 1.11 (0.72-1.71)F 0.864 1.00 (0.67-1.52)F 0.699 0.47 (0.15-1.46)F 0.245
Ethnicity
Asian 4 0.95 (0.77-1.16)F 0.523 0.37 (0.10-1.36)F 0.124 0.96 (0.60-1.52)F 0.960 0.87 (0.55-1.37)F 0.893 0.39 (0.04-3.72)R 0.096
Caucasian 3 0.86 (0.59-1.24)F 0.354 0.89 (0.29-2.78)F 0.944 0.84 (0.54-1.30)F 0.201 0.84 (0.55-1.28)F 0.234 0.95 (0.31-2.95)F 0.984
PCOS diagnostic
criteria
NIH criteria 2 0.65 (0.44-1.02)F 0.869 0.31 (0.08-1.19)F 0.192 0.71 (0.44-1.13)F 0.345 0.65 (0.41-1.03)F 0.638 0.35 (0.09-1.30)F 0.154
Rotterdam criteria 5 1.01 (0.83-1.24)F 0.955 1.02 (0.33-3.19)F 0.991 1.08 (0.70-1.66)F 0.903 1.06 (0.70-1.62)F 0.930 1.05 (0.36-3.07)F 0.993
OR, odds ratio; CI, confidence interval; No., number; vs.: versus; PH, p value of Q-test for heterogeneity test;
Rrandom-effect model; Ffixed-effect model.
athe studies by Zhang et al. and Wen et al. were not included since they presented 0 frequency of AA genotype in cases and controls.
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0.26–1.41; GA vs. GG: OR = 0.89, 95% CI = 0.65–1.23;
AA +GA vs. GG: OR = 0.85, 95% CI = 0.63–1.16; AA vs.
GA +GG: OR = 0.66, 95% CI = 0.29–1.49). After per-
forming stratified analysis for HWE in controls, sample
size ≤ 200, PCR-RFLP, PCOS diagnosis criteria, and ethni-
city separately, the association remained non-significant
(Table 2, Figure 2). In addition, data on genotype distribu-
tions of the TNF-alpha (−308 G/A) polymorphism in
PCOS patients with a body mass index (BMI) ≥ 25 kg/m2
and BMI < 25 kg/m2 were available in three studies
[15-17]. The results showed no significant association of
the TNF-alpha (−308 G/A) polymorphism with obesity inFigure 2 Meta-analysis for the association between the TNF-alpha (−3
based on the dominant model (AA + GA vs. GG; stratified by ethnicitypatients with PCOS (BMI ≥ 25 kg/m2 vs. BMI < 25 kg/m2)
(AA+GA vs. GG: OR= 0.94, 95% CI = 0.49–1.79; Figure 3).
Four studies (351 cases and 464 controls) investigated
the association of the IL-6 (−174 G/C) polymorphism
with PCOS risk and were included in the analysis. Over-
all, no obvious associations were found by heterozygote
comparison (GC vs. GG: OR = 0.54, 95% CI = 0.25–1.17)
or in the dominant model (CC +GC vs. GG: OR = 0.53,
95% CI = 0.26–1.08) and recessive models (CC vs. GC +
GG: OR = 0.67, 95% CI = 0.39–1.16) (Table 3, Figure 4).
However, the results indicated that the IL-6 (−174 G/C)
polymorphism was marginally associated with PCOS in
the allelic model (C vs. G: OR = 0.63, 95% CI = 0.41–08 G/A) polymorphism and risk of polycystic ovary syndrome
).
Figure 3 A forest plot for the correlation of the TNF-alpha (−308 G/A) polymorphism with obesity in patients with polycystic ovary
syndrome (BMI ≥ 25 kg/m2 vs. BMI < 25 kg/m2) based on the dominant model (AA + GA vs. GG; stratified by country).
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0.52, 95% CI = 0.30–0.93). In further subgroup analysis
based on study sample size, the IL-6 (−174 G/C) poly-
morphism was significantly associated with a decreased
PCOS risk among sample size > 200 in the allelic model
(C vs. G: OR = 0.47, 95% CI = 0.28–0.80) and dominant
model (CC +GC vs. GG: OR = 0.32, 95% CI = 0.13–0.78),
as well as by homozygote comparison (CC vs. GG: OR =
0.38, 95% CI = 0.17–0.89) and heterozygote comparison
(GC vs. GG: OR = 0.31, 95% CI = 0.13–0.74). Stratification
by the genotyping method indicated that the examined
SNP was associated with a decreased risk of PCOS among
genotyping method of PCR-RFLP in the allelic model (C
vs. G: OR = 0.49, 95% CI = 0.27–0.88) and by homozygote
comparison (CC vs. GG: OR = 0.31, 95% CI = 0.13–0.72).
Even so, the effect size was not significant among HWE inTable 3 Meta-analysis of IL-6 (−174 G/C) polymorphism and P
Comparison No. of
studies
C vs. G CC vs. GG
OR (95% CI) PH OR (95% CI) PH
Overall 4 0.63 (0.41-0.96)R 0.013 0.52 (0.30-0.93)F 0.329
HWE in controls/
sample size ≤ 200
2 0.84 (0.60-1.16)F 0.157 0.69 (0.32-1.50)F 0.398
Sample size > 200a 2 0.47 (0.28-0.80)R 0.091 0.38 (0.17-0.89)F 0.189
Caucasian 3 0.63 (0.34-1.17)R <0.01 0.48 (0.26-0.91)F 0.211
Genotyping
method
PCR-RFLP 2 0.49 (0.27-0.88)R 0.065 0.31 (0.13-0.72)F 0.461
Pyrosequencing 2 0.80 (0.47-1.37)R 0.092 0.84 (0.38-1.84)F 0.824
OR, odds ratio; CI, confidence interval; No., number; vs.: versus; PH, p value of Q-test
from HWE in controls.controls (sample size ≤ 200) and genotyping method of py-
rosequencing under all genetic models.
Under all genetic models, no obvious associations were
found between the IL-1beta (−511 C/T) polymorphism
and PCOS risk when all studies were pooled into the
meta-analysis (T vs. C: OR = 1.11, 95% CI = 0.67–1.84;
TT vs. CC: OR = 0.89, 95% CI = 0.62–1.27; TC vs. CC:
OR = 0.91, 95% CI = 0.40–2.11; TT + CT vs. CC: OR =
1.0, 95% CI = 0.45–2.19; TT vs. CT + CC: OR = 1.26, 95%
CI = 0.62–2.53). In the subgroup analysis by ethnicity,
HWE in controls, genotyping method, and study sample
size, still no obvious associations were found (Table 4,
Figure 5). Additionally, two studies [24,26] provided data
between the IL-1beta (−511 C/T) polymorphism and sev-
eral clinical and biochemical parameters in patients with
PCOS. The results showed no significant association ofCOS risk
GC vs. GG CC + GC vs. GG CC vs. GC + GG
OR (95% CI) PH OR (95% CI) PH OR (95% CI) PH
0.54 (0.25-1.17)R <0.01 0.53 (0.26-1.08)R <0.01 0.67 (0.39-1.16)F 0.881
0.97 (0.40-2.31)R 0.057 0.88 (0.41-1.92)R 0.074 0.65 (0.31-1.37)F 0.716
0.31 (0.13-0.74)R 0.033 0.32 (0.13-0.78)R 0.074 0.69 (0.30-1.59)F 0.469
0.57 (0.18-1.78)R <0.01 0.54 (0.19-1.55)R <0.01 0.61 (0.33-1.13)F 0.897
0.35 (0.11-1.11)R <0.01 0.35 (0.12-1.03)R <0.01 0.54 (0.24-1.23)F 0.994
0.83 (0.26-2.64)R <0.01 0.80 (0.30-2.10)R 0.019 0.81 (0.38-1.70)F 0.687
for heterogeneity test; Rrandom-effect model; Ffixed-effect model; adeviated
Figure 4 Meta-analysis for the association between the IL-6 (−174 G/C) polymorphism and the risk of polycystic ovary syndrome based
on the dominant model (CC + GC vs. GG; stratified by ethnicity).
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with menarche age (SMD= −0.01, 95% CI = −0.25–0.22),
BMI (SMD= 0.04, 95% CI = −0.20–0.27), and levels of
luteinizing hormone (LH) (SMD= −0.00, 95% CI = −0.24–
0.23), follicle-stimulating hormone (FSH) (SMD= −0.08,
95% CI = −0.32–0.16), total testosterone (SMD = 0.23,
95% CI = −0.01–0.47) and LH/FSH (SMD = 0.05, 95%
CI = −0.19–0.28) in patients with PCOS (Figure 6).
Heterogeneity test and sensitivity analysis
Regarding the TNF-alpha (−308 G/A) polymorphism and
PCOS, there was no heterogeneity among studies in over-
all comparisons (p > 0.10). For the IL-6 (−174 G/C) and
IL-1beta (−511 C/T) polymorphisms and PCOS, there was
statistical significance with between-study heterogen-
eity (p < 0.10). To explore sources of heterogeneity across
studies, subgroup analyses by ethnicity, HWE in con-
trols, genotyping method, and study sample size were
conducted. However, none of these variables could explain
the heterogeneity. To evaluate the stability of the results
of the meta-analysis, sensitivity analyses of the omittedTable 4 Meta-analysis of IL-1beta (−511 C/T) polymorphism an
Comparison No. of
studies
T vs. C TT vs. CC
OR (95% CI) PH OR (95% CI) PH
Overall 4 1.11 (0.67-1.84)R <0.01 0.89 (0.62-1.27)R <0.01
HWE in controls 3 1.08 (0.54-2.14)R <0.01 1.16 (0.29-4.61)R <0.01
Asian/PCR-RFLP 3 1.17 (0.57-2.42)R <0.01 1.29 (0.33-5.09)R <0.01
Sample
size > 200
3 0.90 (0.58-1.37)R 0.014 0.70 (0.47-1.03)R 0.014
OR, odds ratio; CI, confidence interval; No., number; vs.: versus; PH, p value of Q-testindividual studies were performed sequentially. This pro-
cedure confirmed that our results were reliable and robust
(Figure 7).
Publication bias
Publication bias was assessed by both the Begg’s test and
Egger’s test. The statistical results did not show any evi-
dence of publication bias (p > 0.05), with the exception
of the IL-1beta (−511 C/T) polymorphism under the al-
lelic model with the Egger's test (p = 0.023, Table 5). Sen-
sitivity analysis using the trim and fill method was then
performed to assess the possibility of publication bias.
However, no trimming was performed and the data were
unchanged throughout the filled meta-analysis, which sug-
gested the absence of publication bias for the IL-1beta
(−511 C/T) polymorphism under the allelic model.
Discussion
It is well known that PCOS is a proinflammatory state and
chronic low-grade inflammation was found to promote
the development of metabolic disruption and ovariand PCOS risk
TC vs. CC TT + CT vs. CC TT vs. CT + CC
OR (95% CI) PH OR (95% CI) PH OR (95% CI) PH
0.91 (0.40-2.11)R <0.01 1.00 (0.45-2.19)R <0.01 1.26 (0.62-2.53)R <0.01
0.65 (0.33-1.28)R 0.041 0.79 (0.34-1.86)R <0.01 1.50 (0.53-4.25)R <0.01
0.92 (0.27-3.18)R <0.01 1.03 (0.32-3.30)R <0.01 1.37 (0.53-3.54)R <0.01
0.91 (0.31-2.67)R <0.01 0.86 (0.33-2.21)R <0.01 0.83 (0.60-1.14)F 0.769
for heterogeneity test; Rrandom-effect model; Ffixed-effect model.
Figure 5 Meta-analysis for the association between the IL-1beta (−511 C/T) polymorphism and the risk of polycystic ovary syndrome
based on the dominant model (TT + CT vs. CC; stratified by ethnicity).
Figure 6 A forest plot for the correlation of the IL-1beta (−511 C/T) polymorphism (TT + CT vs. CC) with several clinical and biochemical
parameters in patients with polycystic ovary syndrome.
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Figure 7 Sensitivity analysis of the summary odds ratio (OR) coefficients on the associations among the TNF-alpha (−308 G/A), IL-6
(−174 G/C) and IL-1beta (−511 C/T) polymorphisms with the risk of polycystic ovary syndrome based on the dominant model. (A), TNF-alpha
(−308 G/A); (B), IL-6 (−174 G/C); (C), IL-1beta (−511 C/T).
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Table 5 Statistical analyses of publication bias for TNF-alpha, IL-6 and IL-1beta gene polymorphisms
Category Allele model Homozygote comparison Heterozygote comparison Dominant model Recessive model
TNF-alpha (−308 G/A)
Begg’s test 1.00 0.462 0.368 0.133 0.221
Egger’s test 0.704 0.732 0.190 0.180 0.616
IL-6 (−174 G/C)
Begg’s test 0.308 1.00 0.734 0.734 0.734
Egger’s test 0.496 0.729 0.583 0.665 0.906
IL-1beta (−511 C/T)
Begg’s test 0.308 0.308 0.734 0.308 0.089
Egger’s test 0.023 0.089 0.532 0.346 0.178
Guo et al. BMC Genetics  (2015) 16:5 Page 10 of 13dysfunction in PCOS [34]. Moreover, variants in genes
encoding several proinflammatory cytokines and their re-
ceptors associated with obesity, insulin resistance, and dia-
betes have also been found to be associated with PCOS
[17,35]. As common multifunctional cytokines, TNF-alpha,
IL-6, and IL-1 have been proposed to influence the pro-
cesses of ovulation, fertilization, and implantation, which
are also affected in women with PCOS [36]. However, no
significant difference was found by meta-analysis of serum
TNF-alpha and IL-6 concentrations in women with PCOS
and controls, although only nine studies of TNF-alpha and
10 studies of IL-6 were included [37]. The occurrence of
polymorphisms in the TNF-alpha, IL-6, and IL-1 genes in
women affected by PCOS has also been investigated over
the past few decades [22,24]. However, due to the relative
small sample size, no clear consensus has been reached.
The aim of the present study was to perform a meta-
analysis of the best evidence available in an attempt to pro-
vide high-quality data on the linkage between TNF-alpha
(−308 G/A), IL-6 (−174 G/C), and IL-1beta (−511 C/T)
polymorphisms and PCOS risk.
To the best of our knowledge, this is the first meta-analysis
concerning TNF-alpha (−308 G/A), IL-6 (−174 G/C), and
IL-1beta (−511 C/T) polymorphisms and PCOS risk.
Based on our results, no significant association was found
between TNF-alpha (−308 G/A) and IL-1beta (−511 C/T)
polymorphisms and PCOS risk in the overall population
or subgroup analysis under all genetic models. For the
IL-6 (−174 G/C) polymorphism, however, variant C allele
was associated with a lower risk of PCOS in the allelic
model (C vs. G: OR = 0.63, 95% CI = 0.41–0.96) and by
homozygote comparison (CC vs. GG: OR = 0.52, 95%
CI = 0.30–0.93), even though the p-value (0.032 and
0.042, respectively) was marginal. Our results indicate that
the IL-6 (−174 G/C) polymorphism likely conveys a pro-
tective effect against PCOS. A possible explanation for this
finding is that the IL-6 C allele results in low IL-6 produc-
tion, which may normalize ovarian function. However, the
results of this meta-analysis should be cautiously inter-
preted. First, in the subgroup analysis, no association wasfound between the IL-6 (−174 G/C) polymorphism and
PCOS risk by the genotyping method of pyrosequencing
in any genetic model. Although the IL-6 (−174 G/C) poly-
morphism was associated with PCOS in Caucasian popula-
tions and in the subgroup analysis of PCR-RFLP genotyping
method, one study [21] showed deviations in genotype fre-
quency from the HWE of controls. Second, after exclud-
ing two studies with deviations from the HWE in controls
[21,23], which had a sample size of > 200, the result
showed that the IL-6 (−174 G/C) polymorphism was no
longer associated with PCOS. Although the relatively lim-
ited study number (only two studies for IL-6 (−174 G/C)
polymorphism in the subgroup analysis specific to HWE
in controls and genotyping method of pyrosequencing)
and small sample size might have resulted in the null re-
sults, we could not rule out the possibility that the IL-6
(−174 G/C) polymorphism was actually not associated
with PCOS risk. Our overall positive results might be
dominated by the studies showing deviation from the
HWE in controls. No heterogeneity was observed for the
TNF-alpha (−308 G/A) polymorphism. For the IL-6
(−174 G/C) and IL-1beta (−511 C/T) polymorphisms,
however, there was significant heterogeneity in the overall
population and in the subgroup of HWE in controls, eth-
nicity, genotyping method, and sample size that might
have influenced the results. Sensitivity analysis was then
conducted, which confirmed the stability and reliability of
our results.
The pooled results also demonstrated that there was
no obvious association of the TNF-alpha (−308 G/A)
polymorphism with obesity, or between the IL-1beta
(−511 C/T) polymorphism with several clinical and bio-
chemical parameters, in patients with PCOS. However,
It should be noted that not all studies evaluated the ef-
fect of interactions, with two studies [17,26] providing
complete data on different genetic models and three
[15,16,24] just presenting data on the dominant model.
Furthermore, other clinical and laboratory characteristics
(including metabolic parameters and androgen parameters)
according to the genotypes of TNF-alpha (−308 G/A), IL-6
Guo et al. BMC Genetics  (2015) 16:5 Page 11 of 13(−174 G/C), and IL-1beta (−511 C/T) polymorphisms
in the PCOS patients and the control group could not
evaluated due to a lack of sufficient data. Therefore, our
results, which only presented data on the dominant model
of the TNF-alpha (−308 G/A) and IL-1beta (−511 C/T)
polymorphisms, should be interpreted with caution. Insu-
lin resistance and hyperinsulinemia are the central fea-
tures of the metabolic disturbances typical for PCOS [37].
The TNF-alpha (−308 G/A) polymorphism was reported
to be associated with altered responses to oral glucose
tolerance testing in the PCOS group [14]. TNF-alpha is
over-expressed in the adipose tissue of obese subjects
in proportion to the degree of insulin resistance [38]. The
IL-6 polymorphism investigated in this study was shown to
be associated with lipid abnormalities and impaired insulin
sensitivity [39,40]. IL-1beta was proposed as a promoter of
nitrogen (NO) generation and apoptosis of pancreatic islet
B cell, which also induced insulin resistance [26]. However,
a study by Puder et al. showed that an increase in both
low-grade chronic inflammation and insulin resistance in
PCOS patients is associated with increased central fat ex-
cess rather than PCOS status [41]. It remains to be estab-
lished whether the proinflammatory state in PCOS is
primarily a result of genetic variation or simply inflamed
adipose tissue, because there is an increased prevalence of
abdominal adiposity in PCOS across all weight classes. In
fact, no differences were reported in levels of TNF-alpha,
IL-6, and markers of inflammation between obese women
with PCOS and obese controls [42]. A study by Mohlig
et al. also showed that plasma levels of IL-6 and C-reactive
protein were not increased in women with PCOS when
compared to controls matched by age and BMI [43]. Previ-
ous studies have proposed that polymorphisms to the
TNF-alpha (−308 G/A) and IL-1beta (−511 C/T) genes
might be the genetic basis for the increase in TNF-alpha
and IL-1beta serum levels in patients with PCOS [7,24].
Regarding the IL-6 (−174 G/C) polymorphism, however,
several investigations have reported that the homozygous
CC genotype was associated with higher serum IL-6 levels,
which is in contrast to studies indicating that the G
allele is associated with increased IL-6 secretion in sub-
jects with PCOS, metabolic syndrome, and insulin resist-
ance [12,22,39,44]. It appears that transcriptional control
of IL-6 is multifaceted and may be dependent on the im-
pact of other sites of polymorphisms which may be in
linkage disequilibrium with the IL-6 gene locus [45]. Fur-
thermore, it has been suggested that obesity-associated
genes, environmental factors, and gene–environment in-
teractions, as well as dietary habits are also responsible for
the increasing prevalence of PCOS worldwide [17,46,47].
Several limitations to this study need to be taken into
account when interpreting our results. First, the number
of study and the sample sizes were relatively small for
analysis of each gene polymorphism thereby havinginsufficient power to detect any true difference between
cases and controls. Second, heterogeneity was detected in
the IL-1beta (−511 C/T) polymorphisms and the source of
heterogeneity could not be identified due to the limited
number of studies included in each pooled outcome.
Third, the results of our meta-analysis were not adjusted
for confounding factors, such as age and BMI, due to the
lack of sufficient data, which might have influenced the ef-
fect estimates. Finally, the etiology of PCOS has long been
described as multifactorial; however, it was difficult for us
to analyze interactions between genes, lifestyles, and cer-
tain environmental factors.
Conclusions
In summary, the results of this meta-analysis suggested
that variations of the TNF-alpha (−308 G/A), IL-6
(−174 G/C), and IL-1beta (−511 C/T) genes might not
represent genetic risk factors for PCOS. However, there is
a need for further larger-scale studies, including other loci
of the TNF-alpha, IL-6, and IL-1beta genes, to confirm
our results and elucidate the potential association and in-
fluence of cytokine gene polymorphisms, and gene–envir-
onment interactions on the development of PCOS.Additional file
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